Rare Diseases Europe

Rare Diseases Europe
Name	Rare Diseases Europe
Formation	1990s
Type	Non-profit federation
Headquarters	Brussels, Belgium
Region served	Europe
Membership	Patient organizations

Rare Diseases Europe is a pan-European alliance of patient organizations formed to represent people living with low-prevalence conditions. It serves as a collective voice in interactions with institutions such as the European Commission, the European Parliament, the Council of the European Union, and advisory bodies like the European Medicines Agency. The alliance engages with health stakeholders including the World Health Organization, the Organisation for Economic Co-operation and Development, and national agencies across France, Germany, Italy, Spain, and United Kingdom.

History

The coalition traces roots to patient-driven movements in the late 20th century that followed landmark events like the adoption of orphan drug legislation in the United States and European policy debates in the 1990s European Union summit. Early collaborations involved organizations from Belgium, Netherlands, Sweden, Poland, and Romania and intersected with campaigns around the Orphan Drug Act influences and initiatives linked to the Council of Europe. Engagements with figures and institutions such as the European Commission Directorate-General for Health and Food Safety, the European Parliament Committee on the Environment, Public Health and Food Safety, and advisors to the World Health Assembly shaped formalization. Milestones include coordinated responses to regulatory proposals from the European Medicines Agency and participation in multi-stakeholder fora alongside the European Patients' Forum and disease-specific coalitions like EURORDIS-rare diseases Europe partners and national coalitions in Ireland and Portugal.

Mission and Objectives

The alliance’s mission emphasizes improving diagnosis, care, and treatment access for people with low-prevalence conditions by influencing policy in venues such as the European Commission, the European Parliament, and national health ministries in Austria and Greece. Objectives include promoting research priorities aligned with calls from the Horizon 2020 and Horizon Europe programs, reinforcing registries like those endorsed by the European Reference Networks, and advocating for reimbursement frameworks considered by courts such as the Court of Justice of the European Union. Stakeholder engagement spans collaborations with the European Chronic Disease Alliance, the International Rare Diseases Research Consortium, and patient advocacy from groups in Hungary, Bulgaria, and Lithuania.

Governance and Organization

The federation is governed by a board and executive structure interacting with advisory committees modeled after governance seen in institutions like the European Commission and the Council of the European Union. Leadership involves representatives from member organizations across Denmark, Finland, Czech Republic, Slovakia, and Slovenia and consults experts associated with the European Medicines Agency panels and ethics advisors from universities such as University of Oxford and Université Paris-Saclay. Operational offices coordinate policy teams, communications units, and research liaisons who engage with bodies including the European Ombudsman and the European Court of Auditors on transparency and accountability matters.

Activities and Programs

Programs include awareness campaigns timed with international observances like Rare Disease Day and partnership initiatives with research infrastructures such as BBMRI-ERIC and ELIXIR. The organization convenes conferences, webinars, and training workshops featuring speakers from institutions like European Parliament delegations, representatives of the European Commission Directorate-General for Research and Innovation, and academic centers such as Karolinska Institute and Charité – Universitätsmedizin Berlin. Capacity-building activities support national patient groups in Croatia, Estonia, Latvia, and Malta and run projects co-funded alongside EU programs linked to Horizon 2020 consortia, philanthropic foundations like the Bill & Melinda Gates Foundation, and research networks including the European Reference Networks.

Advocacy and Policy Influence

The alliance conducts targeted advocacy on orphan medicinal product regulation, health technology assessment debates in the European Court of Justice context, and cross-border care rules under the Directive on patients' rights in cross-border healthcare. It submits position papers to the European Commission and testifies before committees of the European Parliament, engages with national ministries of health in Poland and Spain, and partners with coalitions such as the European Patients' Forum and the European AIDS Treatment Group on shared priorities. Campaigns have referenced instruments like the Pharmaceuticals Directive and contributed to consultations tied to Horizon Europe work programs and the European Health Data Space.

Research and Collaboration

Collaborations span consortia including the International Rare Diseases Research Consortium, academic centers like Imperial College London and Université Catholique de Louvain, and infrastructures such as EuroBioBank and European Genome-phenome Archive. The federation supports patient registries interoperable with platforms promoted by the European Reference Networks and liaises with funders including the European Investment Bank and national research councils in Switzerland and Norway. Joint projects have involved partners from Johns Hopkins University and institutions in Canada and Japan to harmonize diagnostic pipelines and participate in multi-center trials reviewed by ethics committees and regulatory authorities like the European Medicines Agency.

Funding and Partnerships

Funding sources include membership contributions, grants from EU programs such as Horizon 2020 and Creative Europe, philanthropic foundations like the Wellcome Trust, and partnerships with industry stakeholders governed by codes of conduct aligned with guidance from the European Medicines Agency. Strategic partnerships involve alliances with the European Patients' Forum, national coalitions across Belgium and Italy, research networks such as BBMRI-ERIC, and donor foundations including the Robert Wood Johnson Foundation. Financial oversight adheres to standards reflected in audits by bodies like the European Court of Auditors and reporting practices common to Brussels-based NGOs interacting with the European Commission.

Category:Patient organizations